Abstract:Two series of new pyridyl-bearing fused bicyclic analogues designed to target the dual-tolerant regions of the non-nucleoside reverse transcriptase inhibitor (NNRTI)-binding pocket were synthesized and evaluated for their anti-HIV activities. Several compounds, such as 6, 14, 15, 21, 30, and 33, were found to be potent inhibitors against the wild-type (WT) HIV-1 strain or multiple NNRTI-resistant strains at low nanomolar levels. Detailed structure–activity relationships were obtained by utilizing the variation of moieties within the corresponding pharmacophores. In vitro metabolic stability profiles and some drug-like properties of selected compounds were assessed, furnishing the preliminary structure–metabolic stability relationships. Furthermore, molecular modeling studies elucidated the binding modes of compounds 6, 15, 21, and 30 in the binding pocket of WT, E138K, K103N, or Y181C HIV-1 RTs. These promising compounds can be used as lead compounds and warrant further structural optimization to yield more active HIV-1 inhibitors.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00987.Molecular formula strings (CSV)In vitro anti-HIV assays in MT-4 cells; WT HIV-1 RT inhibition assays; metabolic stability assays in human liver microsomes; molecular modeling; predicted miLogP and MolLogP values of target compounds and controls; mean distance and standard deviation values for selected ligand–protein contacts in simulated systems; regression analysis of miLogP values and MolLogP values; rmsd profiles for the protein backbone, NNRTI-binding site, and simulated inhibitors for the RT-inhibitor complexes; time-dependent distance distribution for d1–d4 for RT-inhibitor complexes; representation of the molecular interaction potential for the interaction of compounds 6, 15, 21, and 30 with a positively and a negatively charged atom; and 1H NMR, 13C NMR, and ESI-MS spectra for the target compounds (PDF).This article has not yet been cited by other publications.

Design, Synthesis and Evaluation of Novel HIV-1 NNRTIs with Dual Structural Conformations Targeting the Entrance Channel of the NNRTI Binding Pocket

Design, Synthesis and Anti-Hiv Evaluation of Novel Diarylnicotinamide Derivatives (danas) Targeting the Entrance Channel of the NNRTI Binding Pocket Through Structure-Guided Molecular Hybridization

Structure-Based Bioisosterism Design, Synthesis and Biological Evaluation of Novel 1,2,4-Triazin-6-ylthioacetamides As Potent Hiv-1 Nnrtis

Targeting the Hydrophobic Channel of NNIBP: Discovery of Novel 1,2,3-Triazole-derived Diarylpyrimidines As Novel HIV-1 NNRTIs with High Potency Against Wild-Type and K103N Mutant Virus

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.

Design, Synthesis and Anti-Hiv Evaluation of Novel Diarylpyridine Derivatives Targeting the Entrance Channel of NNRTI Binding Pocket.

Design, synthesis, and biological evaluation of benzo[4,5]thieno[2,3- d ]pyrimidine derivatives as novel HIV-1 NNRTIs

Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies

Targeting the Entrance Channel of NNIBP: Discovery of Diarylnicotinamide 1,4-Disubstituted 1,2,3-Triazoles As Novel HIV-1 NNRTIs with High Potency Against Wild-Type and E138K Mutant Virus

Design, Synthesis and Biological Evaluation of 3-Benzyloxy-linked Pyrimidinylphenylamine Derivatives As Potent HIV-1 NNRTIs.

Discovery of Novel Diarylpyrimidine Derivatives As Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site

Design, Synthesis, and Biological Evaluation of Novel 4‐aminopiperidinyl‐linked 3,5‐disubstituted‐1,2,6‐thiadiazine‐1,1‐dione Derivatives As HIV‐1 NNRTIs

Design, Synthesis, and Biological Evaluation of Novel 2‐(pyridin‐3‐yloxy)acetamide Derivatives As Potential Anti‐HIV‐1 Agents

Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.

Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of Novel Purinylthioacetanilides Derivatives As Potent HIV-1 NNRTIs Via a Structure-Based Bioisosterism Approach

Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket

Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs

Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5-b]pyridin-2-ylthioacetanilides as Potent HIV NNRTIs Via a Structure-based Bioisosterism Approach.

Structure-based design of diarylpyrimidines and triarylpyrimidines as potent HIV-1 NNRTIs with improved metabolic stability and drug resistance profiles

Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.

Identification of novel diarylpyrimidine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against wild-type and K103N mutant viruses